Google Scholar Citations
Recently Issued US Patents
(Up to date list consists of more than 30 applications and is available upon request)
1. US Patent Number 8,349,555 B2
Inventor(s): Gennadi V. Glinskii, M.D., Ph.D.
Title: Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
Date of Patent: January 08, 2013
2. US Patent Number 7,890,267 B2
Inventor(s): Gennadi V. Glinsky, M.D., Ph.D.
Title: Prognostic and diagnostic methods for cancer therapy
Date of Patent: February 15, 2011
SELECTED PEER-REVIEWED REFERENCES:
1. Glinsky, G.V., Berezovska, O., Glinskii, A.B. 2005. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. Journal of Clinical Investigation, 115: 1503 -1521. (Cited by 655).
This work describes first clinically-significant implementation of the cross-species mouse/human translational & functional genomics approach resulting in discovery of a death-from-cancer gene expression signature and revealing fundamentally-significant genetic links between the “stemness” and therapy-resistant phenotypes of human malignancies (please see ref. 2).
2. Berezovska, OP, Glinskii, AB, Yang, Z, Li, X-M, Hoffman, RM, Glinsky, GV. 2006. Essential role of the Polycomb Group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle, 5: 1886-1901. (Cited by 125).
This work demonstrates that a concomitant activation of the physically and functionally distinct PRC1 and PRC2 multi-protein complexes of the Polycomb Group (PcG) protein chromatin silencing pathway, previously shown to be essential for maintenance of the “stemness” phenotype, is essential for maintenance of highly metastatic phenotype in experimental settings and associated with increased metastatic potential and high likelihood of therapy failure in clinical settings (please see refs. 1, 3). This is the first example of successful transition from microarray-based discoveries of clinically-relevant stemness pathway (s) using large cell populations and analyses of bulk tumors to a single-cell-level pathway analysis and validation assay of pathway engagement in experimental models and clinical samples (please see ref. 1).
3. Glinsky, G.V., Glinskii, A.B., Stephenson, A.J., Hoffman, R.M., Gerald, W.L. 2004. Expression profiling predicts clinical outcome of prostate cancer. Journal of Clinical Investigation, 113: 913-923. (Cited by 322)
This work describes the first successful application of microarray-based genome-wide expression profiling of human xenografts, xenograft-derived stable cell lines, and clinically-relevant sets of primary human tumors for identification of gene expression signatures of increased likelihood of therapy failure in prostate cancer patients diagnosed with the early-stage disease.
4. Glinsky, G.V., Higashiyama, T., Glinskii, A.B. 2004. Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. Clinical Cancer Res., 10: 2272-2283 (Cited by 79).
One of the first successful examples of development of breast cancer therapy response and patients’ survival predictor algorithms based on genome-wide gene expression profiling of tumor samples, breast cancer cell lines, clinical data, and pathology reports.
5. Glinsky, GV. 2008. “Stemness” genomics law governs clinical behavior of human cancer: Implications for decision making in disease management. Journal of Clinical Oncology, 26: 2846-53. (Cited by 119).
This work describes the key principle of development, validation, and practical implementation of gene expression-based Cancer Therapy Outcome Predictor (CTOP) algorithm.